Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.88 is 13% below its 5-year average of -1.66, around the middle of its 5-year range (-2.74–-0.41).
8.74% above its 12-month average of -2.06.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.43.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.88
EARNINGS PER SHARE (EPS) AVG TTM
-2.06
EARNINGS PER SHARE (EPS) AVG 3Y
-2.07
EARNINGS PER SHARE (EPS) AVG 5Y
-1.66
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.74%
CURRENT VS 3Y AVG
+9.18%
CURRENT VS 5Y AVG
-13.37%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$84.75M
Earnings Per Share (EPS)
-1.88
TTM Avg
-2.06
3Y Avg
-2.07
5Y Avg
-1.66
Market Cap
$84.70M
Earnings Per Share (EPS)
-1.18
TTM Avg
-4.40
3Y Avg
-32.48
5Y Avg
-54.06
Market Cap
$84.00M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$83.96M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
Market Cap
$83.49M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$86.69M
Earnings Per Share (EPS)
0.07
TTM Avg
-0.09
3Y Avg
-1.24
5Y Avg
-1.25
Market Cap
$87.86M
Earnings Per Share (EPS)
-0.60
TTM Avg
-0.82
3Y Avg
-0.86
5Y Avg
-0.88
Market Cap
$88.21M
Earnings Per Share (EPS)
0.08
TTM Avg
-0.19
3Y Avg
-0.36
5Y Avg
-0.27
Market Cap
$81.22M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.32
3Y Avg
-0.23
5Y Avg
-0.23
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $84.75M | -1.88 | -2.06 | -2.07 | -1.66 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | -1.18 | -4.40 | -32.48 | -54.06 |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -0.51 | -0.76 | -0.68 | -1.48 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | -0.19 | -0.58 | -0.69 | -0.67 |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 0.07 | -0.09 | -1.24 | -1.25 |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -0.60 | -0.82 | -0.86 | -0.88 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 0.08 | -0.19 | -0.36 | -0.27 |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -0.48 | -0.32 | -0.23 | -0.23 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -1.17 | -2.88 | -6.48 | -4.74 |
Trailing EPS (TTM)
$-1.88
Forward EPS (Est.)
$-1.85
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.02 |
| 2024-12-31 | -2.10 |
| 2023-12-31 | -2.74 |
| 2022-12-31 | -1.42 |
| 2021-12-31 | -1.26 |
| 2020-12-31 | -0.41 |
